Medical News
Putting Early-Onset Colorectal Cancer on the Map: A Milestone Moment at ESMO GI 2025
At ESMO GI 2025, patient advocate Michael Kecht delivered his first international talk, highlighting the alarming rise in early‑onset colorectal ...
Immunotherapy Added to Chemotherapy Shows Breakthrough Results in Early-Stage Gastric Cancer
Global study brings hope to people diagnosed with early-stage gastric cancer, showing that a combination of immunotherapy and chemotherapy may sign...
Global Oncology Partnership Panel Focuses on Patient Engagement
Patient advocates gathered at the first Global Oncology Partnership Panel (GOPP) meeting hosted by Boehringer Ingelheim in Germany. Workshops and d...
Ensuring Access to Critical Medicines: What Digestive Cancer Patients Need from the Critical Medicines Act
The European Commission’s proposal for a Critical Medicines Act marks a significant step toward securing the supply, availability, and accessib...
Can a Targeted Cancer Drug Help Prevent Recurrence in Gastro-Oesophageal Cancer?
DECIPHER Trial for patients with gastro-oesophageal adenocarcinoma, tests whether a targeted cancer drug can help patients with a hard-to-treat can...
Educational Programme on Metastatic Pancreatic Cancer Now Available
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive and often late-diagnosed cancer with poor prognoses. Early detection remains c...
Advancing Liver Cancer Care: Highlights from the BCLC 2024 Meeting
On November 25th and 26th, DiCE virtually attended the Barcelone Clinic Liver Cancer (BCLC) annual conference, which was titled “Forging a Multid...
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...
New Era in Gastric Cancer Treatment: Zolbetuximab Gains EU Approval
On September 20th, 2024, the European Commission approved zolbetuximab with chemotherapy for advanced Gastric and GastroEsophageal Junction cancers...
The POLAR Promise: Groundbreaking Survival Gains for Targeted Pancreatic Cancer Patients in Phase II Trial
Phase II trial of Pembrolizumab Immunotherapy and Olaparib (POLAR) trial new data presented at the European Society for Medical Oncology (ESMO) 202...